Industries > Pharma > Pharma Leader Series: Top 55 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market 2020

Pharma Leader Series: Top 55 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market 2020

Financial Performances, Services, Capacities, Mergers & Acquisitions, SWOT Analysis

PUBLISHED: 16 January 2020
PAGES: 265
PRODUCT CODE: PHA0667
SUBMARKET: Contract Services

Clear
WOOCS 2.2.1

covid-19

Contract manufacturing represents the largest sector of the pharma outsourcing industry. Pharmaceutical companies have sought to take advantage of the benefits of contract manufacturing – lower costs, increased flexibility and external expertise – to focus resources on core competencies in drug development and marketing.

CMOs are increasingly seen as a strategic partner for pharmaceutical companies, providing a one-stop-shop of services for formulation development and manufacturing throughout the lifecycle of a drug.

The market leading CMOs have grown through acquisitions and site expansions to offer almost all required services on a global scale. However, there is still a role to be played by specialist CMOs, particularly those that offer biological drug manufacturing services.

This updated study discusses market-leading companies worldwide, as well as the strategies they have employed to develop in recent years. Visiongain’s research and analysis explore opportunities and challenges for the top 55 pharma contract manufacturing organisations.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 265-page report you will receive 154 tables and 50 figures– all unavailable elsewhere.

The 265-page report provides clear detailed insight into the leading pharmaceutical contract manufacturing organizations. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Profiles of the 55 leading pharmaceutical CMOs which include:
• AbbVie Contract Manufacturing
• Aenova Group
• Aesica Pharmaceuticals
• Ajinomoto Althea, Inc.
• Albany Molecular Research, Inc.
• Alkermes plc
• Almac Group
• Amatsigroup
• Aurobindo Pharma Ltd.
• Avid Bioservices Inc.
• Baxter Biopharma Solutions
• Bayer AG
• Biophore
• Boehringer Ingelheim GmbH
• Cambrex Corporation
• Cardinal Health
• Catalent Pharma Solutions Inc.
• Charles River Laboratories International Inc.
• Delpharm
• Dr. Reddy’s Laboratories Ltd.
• Evonik Degussa
• Famar Health Care Services
• Fareva
• Fujifilm Diosynth Biotechnologies UK Ltd.
• GlaxoSmithKline plc
• Huapont Medical
• Lonza Group Ltd.
• Nipro Corporation
• Paragon Bioservices Inc
• Patheon Inc
• Pfizer Inc./Pfizer CentreSource (PCS)
• Roche
• Royal DSM NV
• Strides
• Teva API
• Vetter Pharmacuticals
• WuXi AppTec
• Xcelience LLC
• Xcellerex LLC
• Zhejiang Hisun Pharmaceutical
• Other Companies

Top 55 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market 2020

• The content of each profile differs, depending on the organization. In general, a profile gives the following information:
• Overview of the company’s contract manufacturing services and operations
• Analysis of recent financial performance – annual revenue for CMO services, including some data on operating profit and margins
• Assessment of developments – activities, acquisitions, production capacity, deals, new service offerings and collaborations
SWOT analysis – a firm’s strengths and weaknesses, as well as opportunities and threats to manufacturing sales growth

• Key Questions Answered by This Report:
• Who are the leading pharmaceutical contract manufacturers?
• What factors are driving and restraining the growth for leading CMOs?
• How have the leading CMOs performed financially in recent years?
• Which CMOs will experience revenue growth over the coming years?
• What are the strengths and weaknesses for the leading pharmaceutical CMOs?
• How do leading CMOs compare in terms of production capacity and facilities?
• What strategies have CMOs been implementing for sales growth in recent years?
• Which technologies will be crucial to CMOs?

Visiongain’s study is intended for anyone requiring commercial analyses for pharmaceutical contract manufacturing market. You find data, trends and predictions.

Buy our report today Pharma Leader Series: Top 55 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market 2020: Financial Performances, Services, Capacities, Mergers & Acquisitions, SWOT Analysis.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top 55 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market 2020


Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top 55 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market 2020


Latest Pharma news

Visiongain Publishes Generic Drugs Market Report 2020-2030

The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

03 July 2020

READ

Visiongain publishes Clinical Workflow Solutions Market Report 2020-2030

Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

03 July 2020

READ

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

READ

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

READ

Categories